Literature DB >> 20013036

Bifunctional polymeric inhibitors of human influenza A viruses.

Jayanta Haldar1, Luis Alvarez de Cienfuegos, Terrence M Tumpey, Larisa V Gubareva, Jianzhu Chen, Alexander M Klibanov.   

Abstract

PURPOSE: New antiviral agents were prepared by attaching derivatives of sialic acid (1) and of the drug zanamivir (2) to poly(isobutylene-alt-maleic anhydride) (poly-(1 + 2)) or by mixing poly-1 and poly-2, followed by assaying them against wild-type and drug-resistant influenza A Wuhan viruses.
METHODS: Individually or together, 1 and 2 were covalently bonded to the polymer. The antiviral potencies of the resultant poly-1, poly-2, poly-(1 + 2), and poly-1 + poly-2, as well as 1 and 2, were assessed using plaque reduction assay.
RESULTS: Attaching 1 to the polymer improved at best millimolar IC(50) values over three orders of magnitude. While 2 exhibited micromolar IC(50) values, poly-2 was >100-fold even more potent. The IC(50) of poly-(1 + 2) against the wild-type strain was >300-fold and approximately 17-fold better than of poly-1 and poly-2, respectively. In contrast, the potency of poly-(1 + 2) vs. poly-2 against the mutant strain merely doubled. The mixture of poly-1 + poly-2 inhibited both viral strains similarly to poly-2.
CONCLUSIONS: The bifunctional poly-(1 + 2) acts synergistically against the wild-type influenza virus, but not against its drug-resistant mutant, as compared to a physical mixture of the monofunctional poly-1 and poly-2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013036      PMCID: PMC2847411          DOI: 10.1007/s11095-009-0013-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.

Authors:  D M Andrews; P C Cherry; D C Humber; P S Jones; S P Keeling; P F Martin; C D Shaw; S Swanson
Journal:  Eur J Med Chem       Date:  1999 Jul-Aug       Impact factor: 6.514

2.  Carbohydrate materials bearing neuraminidase-resistant C-glycosides of sialic acid strongly inhibit the in vitro infectivity of influenza virus.

Authors:  J O Nagy; P Wang; J H Gilbert; M E Schaefer; T G Hill; M R Callstrom; M D Bednarski
Journal:  J Med Chem       Date:  1992-11-13       Impact factor: 7.446

3.  Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.

Authors:  Jayanta Haldar; Jianzhu Chen; Terrence M Tumpey; Larisa V Gubareva; Alexander M Klibanov
Journal:  Biotechnol Lett       Date:  2007-10-31       Impact factor: 2.461

4.  Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Authors:  Hui-Ling Yen; Louise M Herlocher; Erich Hoffmann; Mikhail N Matrosovich; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems.

Authors:  W J Lees; A Spaltenstein; J E Kingery-Wood; G M Whitesides
Journal:  J Med Chem       Date:  1994-09-30       Impact factor: 7.446

6.  Synthetic polymeric sialoside inhibitors of influenza virus receptor-binding activity.

Authors:  M N Matrosovich; L V Mochalova; V P Marinina; N E Byramova; N V Bovin
Journal:  FEBS Lett       Date:  1990-10-15       Impact factor: 4.124

7.  Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition.

Authors:  M Mammen; G Dahmann; G M Whitesides
Journal:  J Med Chem       Date:  1995-10-13       Impact factor: 7.446

8.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

Authors:  M Louise Herlocher; Rachel Truscon; Stephanie Elias; Hui-Ling Yen; Noel A Roberts; Suzanne E Ohmit; Arnold S Monto
Journal:  J Infect Dis       Date:  2004-09-28       Impact factor: 5.226

9.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.

Authors:  Takeshi Masuda; Shuku Yoshida; Masami Arai; Satoru Kaneko; Makoto Yamashita; Takeshi Honda
Journal:  Chem Pharm Bull (Tokyo)       Date:  2003-12       Impact factor: 1.645

View more
  10 in total

1.  Conjugation to polymeric chains of influenza drugs targeting M2 ion channels partially restores inhibition of drug-resistant mutants.

Authors:  Alyssa M Larson; Jianzhu Chen; Alexander M Klibanov
Journal:  J Pharm Sci       Date:  2013-07-06       Impact factor: 3.534

2.  Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.

Authors:  Alisha K Weight; Jayanta Haldar; Luis Alvarez de Cienfuegos; Larisa V Gubareva; Terrence M Tumpey; Jianzhu Chen; Alexander M Klibanov
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

3.  Zanamivir conjugated to poly-L-glutamine is much more active against influenza viruses in mice and ferrets than the drug itself.

Authors:  Alisha K Weight; Jessica A Belser; Terrence M Tumpey; Jianzhu Chen; Alexander M Klibanov
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

4.  Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection.

Authors:  Chia Min Lee; Alisha K Weight; Jayanta Haldar; Ling Wang; Alexander M Klibanov; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

5.  Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition.

Authors:  Daniel Lauster; Maria Glanz; Markus Bardua; Kai Ludwig; Markus Hellmund; Ute Hoffmann; Alf Hamann; Christoph Böttcher; Rainer Haag; Christian P R Hackenberger; Andreas Herrmann
Journal:  Angew Chem Int Ed Engl       Date:  2017-04-26       Impact factor: 15.336

6.  Topology-Matching Design of an Influenza-Neutralizing Spiky Nanoparticle-Based Inhibitor with a Dual Mode of Action.

Authors:  Chuanxiong Nie; Badri Parshad; Sumati Bhatia; Chong Cheng; Marlena Stadtmüller; Alexander Oehrl; Yannic Kerkhoff; Thorsten Wolff; Rainer Haag
Journal:  Angew Chem Weinheim Bergstr Ger       Date:  2020-07-08

Review 7.  Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.

Authors:  Hanadi Sinokrot; Tasneem Smerat; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2017-10-16       Impact factor: 4.411

Review 8.  Development of effective anti-influenza drugs: congeners and conjugates - a review.

Authors:  Jiun-Jie Shie; Jim-Min Fang
Journal:  J Biomed Sci       Date:  2019-10-23       Impact factor: 8.410

9.  Design and Functional Analysis of Heterobifunctional Multivalent Phage Capsid Inhibitors Blocking the Entry of Influenza Virus.

Authors:  Lutz Adam; Eva Müller; Kai Ludwig; Simon Klenk; Daniel Lauster; Susanne Liese; Andreas Herrmann; Christian P R Hackenberger
Journal:  Bioconjug Chem       Date:  2022-06-27       Impact factor: 6.069

10.  Synthetic Glycomacromolecules of Defined Valency, Absolute Configuration, and Topology Distinguish between Human Lectins.

Authors:  Manuel Hartweg; Yivan Jiang; Gokhan Yilmaz; Cassie M Jarvis; Hung V-T Nguyen; Gastón A Primo; Alessandra Monaco; Valentin P Beyer; Kathleen K Chen; Somesh Mohapatra; Simon Axelrod; Rafael Gómez-Bombarelli; Laura L Kiessling; C Remzi Becer; Jeremiah A Johnson
Journal:  JACS Au       Date:  2021-08-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.